Pharmaspire

EDITORIAL

Role of regulatory affairs in nanoparticles formulation

Amrinder Singh

Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India

ABSTRACT

Nanoparticles are small particles that have a wide range of potential applications, including drug delivery, imaging, and diagnostics. However, the safety and efficacy of nanoparticles are still not fully understood, and there are concerns about their potential to cause toxicity. Regulatory affairs professionals play a key role in ensuring the safety and efficacy of nanoparticles by interpreting and applying regulatory guidelines, conducting safety assessments, and preparing regulatory submissions. They also communicate with regulatory agencies throughout the development and commercialization of nanoparticle products. By carefully performing these tasks, regulatory affairs professionals can help to bring these innovative products to market while protecting the public health. The role of regulatory affairs in nanoparticles formulation is complex and challenging, but it is essential to ensure the safety and efficacy of these innovative products. By carefully performing their duties, regulatory affairs professionals can help to bring these products to market and improve the lives of millions of people.

KEY WORDS: Novel drug delivery systems, Pharmaceutics, Regulatory affairs, Regulatory bodies

INTRODUCTION

The role of regulatory in pharma is to ensure that drugs are safe and effective for human use. This is done by setting standards and guidelines for the development and approval of drugs, reviewing and approving drugs before they can be marketed, and monitoring drugs after they have been approved.[1,2]

There are several reasons why regulatory is needed in pharma. First, it is important to protect the public health.[3] Drugs can have serious side effects, and regulatory helps to ensure that these risks are minimized. Second, regulatory helps to ensure that drugs are effective. Drugs that are not effective are not worth the risk, and regulatory helps to ensure that only effective drugs are approved. Third, regulatory helps to ensure that drugs are manufactured and distributed in a safe and consistent manner. This is important to ensure that patients receive the same quality of care regardless of where they live.[4]

Need of regulatory affairs along with recent examples

- In the past, there were many drugs that were approved that turned out to be unsafe. For example, thalidomide was a drug that was approved in the 1950s to treat morning sickness. However, it was later found to cause birth defects. Regulatory helps to prevent these types of tragedies from happening again.[5]
- In the early 2000s, there was a scandal involving the marketing of Vioxx, a painkiller. Vioxx was approved by the Food and Drug Administration (FDA), but it was later found to increase the risk of heart attacks and strokes. Regulatory helps to ensure that drugs are not approved if they have serious safety risks.
- In recent years, there have been several cases of counterfeit drugs being sold. Counterfeit drugs are often made with dangerous ingredients, and they can be ineffective or even deadly. Regulatory helps to prevent counterfeit drugs from entering the market.[6]

Overall, the function of regulation in pharma is critical to public health protection. Regulatory helps to guarantee that pharmaceuticals are safe, effective, and made in a safe

Address for Correspondence:
Amrinder Singh,
E-mail: amrinder.aulakh@yahoo.com

Access this article online

Website: http://isfcppharmaspire.com

DOI: 10.56933/Pharmaspire.2023.15132

Date of Submission: 10 July 2023
Date of Revision: 14 July 2023
Date of Acceptance: 17 July 2023

and consistent manner by creating standards and norms, evaluating and approving drugs, and monitoring drugs.

MATERIALS AND METHODS REQUIRED FOR PREPARATION OF NDDS

The materials and methods required for the preparation of Novel Drug Delivery System (NDDS) vary depending on the specific type of system being developed. However, some common materials and methods include:

Materials

- Drugs
- Polymers
- Lipids
- Surfactants
- Colloids
- Metals
- Inorganic materials

Method

- Solvent casting
- Emulsion methods
- Self-assembly
- Electro spraying
- Sonoporation
- Microfluidics

The choice of materials and methods will depend on the desired properties of the NDDS, such as its stability, solubility, targeting ability, and release profile. For example, if the goal is to develop a NDDS that can target a specific cell type, then the materials and methods used will be different from those used to develop a NDDS that is designed to release the drug slowly over time.[7]

The future of regulatory affairs in nanoparticles formulation is bright. As the field of nanotechnology continues to grow, the need for regulatory guidance and expertise will increase. Regulatory affairs professionals will be essential and ensuring the safety and efficacy of these products, and they will play a key role in the future of nanotechnology.

Here are some additional thoughts on the role of regulatory affairs in nanoparticles formulation:

- The regulatory landscape for nanoparticles is still evolving, and it is important for regulatory affairs professionals to stay up-to-date on the latest developments.
- The safety and efficacy of nanoparticles is a complex issue, and there is still much that we do not know about these products. Regulatory affairs professionals will need to work closely with scientists and clinicians to gather the necessary data to support the safe and effective use of nanoparticles.
- The future of regulatory affairs in nanoparticles formulation is promising, and regulatory affairs professionals will play a key role in ensuring the safe and effective development and use of these products.

Novel drug delivery system

A novel drug delivery system (NDDS) is a formulation or device that distributes a medicine at a precise rate to a specific place in the body. NDDSs are intended to increase the effectiveness, safety, and ease of use of pharmacological treatment.[8]

Various types of novel drug delivery systems

- Liposomes: Liposomes are tiny sacs made of phospholipids that can encapsulate drugs. Liposomes can be used to deliver drugs to specific tissues or cells.
- Nanoparticles: Nanoparticles are tiny particles that can be used to deliver drugs. Nanoparticles can be made of a variety of materials, including polymers, lipids, and metals.[9]
- Microspheres: Microspheres are tiny spheres that can be used to deliver drugs. Microspheres can be made of a variety of materials, including polymers, lipids, and metals.
- Dendrimers: Dendrimers are branched molecules that can be used to deliver drugs. Dendrimers can be made of a variety of materials, including polymers and metals.
- Gene therapy: Gene therapy is a type of NDDS that uses genetic material to deliver drugs to cells. Gene therapy can be used to treat a variety of diseases, including cancer and HIV/AIDS.[10]

NDDS are still under development, but they have the potential to revolutionize drug therapy. NDDS could make drugs more effective, safer, and more convenient to use. They could also make it possible to treat diseases that were previously untreatable.

Advantages of NDDSs

- Increased efficacy: NDDSs can improve the efficacy of drugs by delivering them to the target site in the body more effectively. This can lead to better clinical outcomes.[11]
- Improved safety: NDDSs can improve the safety of drugs by reducing the risk of side effects. This is because NDDSs can deliver drugs to the target site in the body, where they are less likely to cause side effects.[12]
- Greater convenience: NDDSs can make drug therapy more convenient by reducing the frequency of dosing. This can improve patient compliance and make it easier to manage chronic diseases.

NDDSs represent an exciting new field of drug delivery research. As these technologies advance, they have the potential to transform medication therapy and enhance the lives of millions of people.[13]

Novel drug delivery systems (NDDS) are a promising new area of drug delivery research. However, there are still some limitations to these systems. Some of the limitations of NDDS include:

- Cost: NDDS can be more expensive to develop and manufacture than traditional drug delivery systems. This is because NDDS often require complex manufacturing processes and specialized equipment.
- Safety: NDDS can be more challenging to ensure the safety of than traditional drug delivery systems. This is because NDDS can interact with the body in different ways than traditional drug delivery systems.
- Efficacy: The efficacy of NDDS can be variable. This is because the way that NDDS interact with the body can vary depending on a number of factors, such as the patient's individual physiology and the disease being treated.[14]
- Tolerability: NDDS can sometimes cause side effects. These side effects can be due to the way that NDDS interact with the body or to the materials that are used to make NDDS.
- Regulatory approval: NDDS can be more challenging to get regulatory approval for than traditional drug delivery systems. This is because NDDS are often considered to be "new drugs" and they need to be evaluated through a more rigorous regulatory process.

Despite these limitations, NDDS have the potential to revolutionize drug therapy. As these technologies continue to develop, they have the potential to make drugs more effective, safer, and more convenient to use.[15]

Here are some additional challenges that need to be addressed to overcome the limitations of NDDS:

- The need for more research: There is still a need for more research on NDDS. This research is needed to better understand how NDDS interact with the body and to identify ways to improve their safety and efficacy.[16]
- The need for better manufacturing processes: There is also a need for better manufacturing processes for NDDS. These processes need to be able to produce NDDS that are consistent in quality and that meet the required safety standards.
- The need for better regulatory approval processes: The regulatory approval process for NDDS needs to be improved. This process needs to be more efficient and it needs to be able to keep up with the pace of technological development.[17]

Overall, the limitations of NDDS are significant, but they are not insurmountable. As research in this area continues, it is likely that these limitations will be overcome and that NDDS will become a more widespread and accepted form of drug delivery.[18]

- Therapeutic goal: The first step in developing a novel drug delivery system is to define the therapeutic goal. What is the disease or condition that the system is intended to treat? What are the desired effects of the drug.[19]
- Drug properties: The next step is to consider the properties of the drug that will be delivered by the system. What is the solubility of the drug? What is its stability? What are its toxicity concerns.
- Target tissue or cells: The system must be designed to target the specific tissue or cells that the drug is intended to affect. This may involve using a system that can be delivered to a specific location in the body, or a system that can release the drug in a controlled manner.
- Route of administration: The route of administration is also an important consideration. Some systems are designed to be administered orally, while others are designed to be administered by injection or inhalation.
- Biocompatibility: The system must be biocompatible, meaning that it must not cause any harm to the body. This is especially important for systems that are designed to be administered for long periods of time.
- Manufacturing process: The manufacturing process must be able to produce the system in a consistent and reproducible manner. This is important to ensure that the system is safe and effective.
- Regulatory approval: The system will need to be approved by regulatory agencies before it can be marketed. This process can be long and complex, so it is important to start the approval process early in the development process.

By considering these important factors, developers can create novel drug delivery systems that are safe, effective, and convenient for patients.[20]

Here are some additional considerations that may be important depending on the specific novel drug delivery system.

- The stability of the drug in the system: The drug must be stable in the system and not degrade over time.
- The ability of the system to release the drug at a controlled rate: The system must release the drug at a rate that is appropriate for the therapeutic goal.
- The ability of the system to target the drug to specific tissues or cells: The system must be able to target the drug to the specific tissues or cells that it is intended to affect.
- The cost of the system: The cost of the system must be affordable for patients.

By considering all of these factors, developers can create novel drug delivery systems that are safe, effective, and convenient for patients.

The role of regulatory bodies in novel drug delivery systems (NDDS)

The purpose of NDDS is to assure that these goods are safe and effective for human use. This entails a variety of responsibilities, including.[21]

- Setting standards and guidelines: Regulatory bodies set standards and guidelines for the development and approval of NDDS. These standards and guidelines vary from country to country, but they typically cover areas such as the safety and efficacy of the product, the manufacturing process, and the labeling.
- Reviewing and approving NDDS: Regulatory bodies review and approve NDDS before they can be marketed. This process involves evaluating the safety and efficacy data for the product, as well as the manufacturing process.
- Monitoring NDDS: Regulatory bodies monitor NDDS after they have been approved. This involves collecting data on the safety and efficacy of the product, as well as any adverse events.

NDDS regulatory agencies play an important role in ensuring that these products are safe and effective for human consumption. Regulatory authorities work to protect public health by creating standards and norms, examining and approving NDDS, and monitoring NDDS.[22]

Here are some specific examples of the role of regulatory bodies in NDDS as shown in Figure 1.

- The US FDA regulates NDDS in the United States. The FDA has a number of guidelines for the development and approval of NDDS, including the "Guidance for Industry: Nanotechnology-Based Drug Products" and the Guidance for Industry: Development and Manufacture of Drug Products Reconstituted at the Point-of-Care.
- The European Medicines Agency (EMA) regulates NDDS in the European Union. The EMA has a number of guidelines for the development and approval of NDDS, including the "Guideline on Nanomedicines" and the Guideline on the Development of Drug Products Reconstituted at the Point-of-Care.
- The World Health Organization (WHO) also has guidelines for the development and approval of NDDS. The WHO's guidelines are designed to help countries develop their own regulatory frameworks for NDDS.

As these medications become more extensively utilized, the role of regulatory organizations in NDDS is changing. To assure the safety and efficacy of NDDS as they become more complicated, regulatory agencies will need to set new criteria and recommendations.[23]

The future of regulatory affairs in pharmaceutics is bright. The field is expected to grow significantly in the coming years, as the pharmaceutical industry continues to develop new and innovative products.

Here are some of the trends that are shaping the future of regulatory affairs in pharmaceutics:

- The rise of digital health: Digital health is rapidly changing the way that healthcare is delivered. This is also having a significant impact on the regulatory landscape, as regulators are increasingly looking at ways to regulate digital health products. Regulatory affairs professionals will need to be familiar with these new technologies and how they are regulated.
- The increasing focus on patient safety: Patient safety is a top priority for regulators around the world. Regulatory affairs professionals will need to be able to demonstrate how their products are safe and effective. They will also need to be able to communicate effectively with patients and their families about the risks and benefits of their products (Table 1).



Figure 1: Various regulatory bodies

Table 1: NDDS-based formulation approved by regulatory bodies.[22]

Novel drug delivery system	Regulatory agency	Regulatory approval
Liposomes	US food and drug administration	Approved for the treatment of cancer, HIV/AIDS, and other diseases.
Nanoparticles	FDA	Approved for the treatment of cancer, Alzheimer's disease, and other diseases.
Microspheres	FDA	Approved for the treatment of cancer, pain, and other diseases.
Dendrimers	FDA	Approved for the treatment of cancer and other diseases.
Gene therapy	FDA	Approved for the treatment of cancer, HIV/AIDS, and other diseases.

- The growth of global markets: The pharmaceutical industry is increasingly globalized, as companies look to expand their reach into new markets. This means that regulatory affairs professionals will need to be familiar with the regulatory requirements of multiple jurisdictions.[24] They will also need to be able to work effectively with cross-functional teams to ensure that products are compliant with all applicable regulations.

FUTURE ASPECTS

The future of regulatory affairs in the pharmaceutical sector is bright. As the industry continues to evolve, so too will the role of regulatory affairs professionals.

Here are some of the trends that are shaping the future of regulatory affairs in the pharmaceutical sector:

- The rise of digital health: The rise of digital health is creating new opportunities for regulatory affairs professionals. For example, regulatory affairs professionals will need to be involved in the development and approval of digital health products, such as mobile apps and wearable devices.
- The increasing focus on personalized medicine: The increasing focus on personalized medicine is also creating new opportunities for regulatory affairs professionals. Regulatory affairs professionals will need to be involved in the development and approval of personalized medicine products, which are designed to treat specific individuals or groups of individuals.
- The need for global harmonization: The need for global harmonization is another trend that is shaping the future of regulatory affairs. As the pharmaceutical industry becomes more globalized, there is a growing need for regulatory standards that are harmonized across different countries. Regulatory affairs professionals will need to be involved in the development and implementation of these harmonized standards.
- The use of artificial intelligence and machine learning: The use of artificial intelligence and machine learning is another trend that is shaping the future of regulatory affairs. These technologies can be used to automate many of the tasks that are currently performed by regulatory affairs professionals, such as data analysis and risk assessment. This will free up regulatory affairs professionals to focus on more strategic tasks, such as developing new regulatory strategies and managing regulatory relationships.

Overall, the future of regulatory affairs in the pharmaceutical industry is promising. As the industry evolves, so will the job of regulatory affairs experts. Regulatory affairs specialists who can adapt to these developments will be in great demand.[19]

In addition to the trends mentioned above, here are some other factors that are likely to shape the future of regulatory affairs in the pharmaceutical sector.[25]

- The increasing importance of patient safety: As the pharmaceutical industry becomes more complex, there is a growing focus on patient safety. Regulatory affairs professionals will need to be involved in ensuring that new drugs and therapies are safe for patients.
- The growing role of data analytics: Data analytics is becoming increasingly important in the pharmaceutical industry. Regulatory affairs professionals will need to be able to use data analytics to assess the safety and efficacy of new drugs and therapies.
- The increasing importance of stakeholder engagement: Regulatory affairs professionals will need to be able to effectively engage with stakeholders, such as patients, health-care professionals, and regulatory agencies.

The future of regulatory affairs in the pharmaceutical sector is bright. By adapting to the changing landscape and developing the necessary skills, regulatory affairs professionals will be well-positioned for success in the years to come.[26]

The findings of a study on the function of regulatory affairs in nanoparticle formation revealed the necessity for clear and consistent regulatory guidelines for these products. Because the existing regulatory landscape is complicated and fragmented, firms may find it challenging to develop and commercialize nanoparticle-based medicines. More study on the safety and efficacy of nanoparticles is also needed, according to the findings. The long-term consequences of nanoparticles on human health are yet unknown, and this is an important topic of research.[27]

The research on the role of regulatory affairs in nanoparticles formulation has highlighted the importance of this issue. Regulatory affairs professionals play a critical role in

ensuring the safety and efficacy of these products, and they will be essential to the future development of nanoparticle-based therapies.

The research has also shown that there is a need for more research on the safety and efficacy of nanoparticles. This is an important area of research, and it is essential to ensure that these products are safe and effective before they are made available to patients.

The future of regulatory affairs in nanoparticles formulation is bright. As the field of nanotechnology continues to grow, the need for regulatory guidance and expertise will increase. Regulatory affairs professionals will be essential to ensuring the safety and efficacy of these products, and they will play a key role in the future of nanotechnology.[28]

CONCLUSION

The role of regulatory affairs in nanoparticles formulation is to ensure the safety and efficacy of these products. This involves a number of tasks, including:

- Understanding the regulatory landscape for nanoparticles. This includes familiarizing oneself with the regulations of relevant regulatory bodies, such as the FDA, EMA, and WHO.
- Evaluating the safety of nanoparticles. This involves assessing the potential risks of nanoparticles, such as toxicity, bio distribution, and environmental impact.
- Demonstrating the efficacy of nanoparticles. This involves conducting clinical trials to show that nanoparticles are effective in treating diseases.
- Preparing regulatory submissions. This involves drafting and submitting regulatory documents, such as Investigational new drug applications and new drug applications.
- Managing regulatory interactions. This involves communicating with regulatory bodies and responding to their questions and requests.

The role of regulatory affairs in nanoparticles formulation is essential to ensure the safety and efficacy of these products. By carrying out these tasks, regulatory affairs professionals help to protect patients and promote the development of new and innovative nanoparticle-based therapies.

In addition to the tasks listed above, regulatory affairs professionals may also be involved in other aspects of the development and commercialization of nanoparticles, such as:

- Developing and implementing quality assurance and quality control procedures.
- Training personnel on regulatory requirements.
- Providing regulatory support to marketing and sales teams.

The role of regulatory affairs in nanoparticles formulation is a complex and challenging one, but it is essential to the success of these products. By working closely with scientists, clinicians, and other stakeholders, regulatory affairs professionals can help to bring safe and effective nanoparticle-based therapies to patients.

REFERENCES

1. Löbenberg R, Amidon GL. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm 2000;50:3-12.
2. Tinkle S, McNeil SE, Mühlebach S, Bawa R, Borchard G, Barenholz Y, *et al*. Nanomedicines: Addressing the scientific and regulatory gap. Ann N Y Acad Sci 2014;1313:35-56.
3. Halwani AA. Development of pharmaceutical nanomedicines: From the bench to the market. Pharmaceutics 2022;14:106.
4. Asif M, Alam M, Alam Q. Future of pharmaceutical marketing in India-an extensive review. Int J Pharma Profess Res 2023;14:164-85.
5. Fahmi HL, Al-Jumaili AA, Younus MM. The whole experience of public hospital physicians from several specialties with biopharmaceutical effectiveness, safety, adverse drug reactions and interchangeability: A qualitative study. Explor Res Clin Soc Pharm 2022;7:100162.
6. Tantray J, Zaid M, Kosey S, Patel A, Sharma AK, Sharma R, *et al*. Pharmacovigilance: A meta-analysis on ADRS of past and recent tragedy occurred in Gambia. J Pharmacovigil 2023;11:409.
7. Heims E, Moxon S. Mechanisms of regulatory capture: Testing claims of industry influence in the case of *Vioxx*. In: Regulation and Governance. United States: Wiley; 2023.
8. Ziavrou KS, Noguera S, Boumba VA. Trends in counterfeit drugs and pharmaceuticals before and during COVID-19 pandemic. Forensic Sci Int 2022;338:111382.
9. Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu ZX, Chen ZS, *et al*. Nano-drug delivery systems entrapping natural bioactive compounds for cancer: Recent progress and future challenges. Front Oncol 2022;12:867655.
10. Andra VV, Pammi SV, Bhat Raju LV, Ruddaraju LK. A comprehensive review on novel liposomal methodologies, commercial formulations, clinical trials and patents. Bionanoscience 2022;12:274-91.
11. Xu L, Wang X, Liu Y, Yang G, Falconer RJ, Zhao CX. Lipid nanoparticles for drug delivery. Adv NanoBiomed Res 2022;2:2100109.
12. Ding H, Tan P, Fu S, Tian X, Zhang H, Ma X, *et al*. Preparation and application of pH-responsive drug delivery systems. J Control Release 2022; 48:206-38.
13. Li H, Zha S, Li H, Liu H, Wong KL, All AH. Polymeric dendrimers as nanocarrier vectors for neurotheranostics.

Small 2022;18:e2203629.
14. Jena R, Vishwas S, Kumar R, Kaur J, Khursheed R, Gulati M, *et al*. Treatment strategies for HIV infection with emphasis on role of CRISPR/Cas9 gene: Success so far and road ahead. Eur J Pharmacol 2022;931:175173.
15. Liu W, Ma Z, Wang Y, Yang J. Multiple nano-drug delivery systems for intervertebral disc degeneration: Current status and future perspectives. Bioact Mater 2023;23:274-99.
16. Banafar A, Shukla SS, Tiwari SP, Kaur CD, Turkane DR, Thakur AS, *et al*. Enhancement of bioavailability of some cardiovascular drugs by novel nano-carrier delivery system. Acta Sci Pharm Sci 2022;6:24-32.
17. Sharma A, Shamkhani D, Pandey S, Singh J, Lalhlenmawia H, Kumarasamy M, *et al*. Advances in lung cancer treatment using nanomedicines. ACS Omega 2022;8:10-41.
18. He S, Pan H, Zhang J. Advances of typical mesoporous materials and the application in drug delivery. Mater Res Express 2023;10:042001.
19. Shekhar S, Kumar A, Rana V, Kumar R, Mittal C, Tariyal K. Recent approaches of matrix release tablet in NDDS system. J Res Appl Sci Biotechnol 2023;2:64-71.
20. Deshmukh R. Rheumatoid arthritis: Pathophysiology, current therapeutic strategies and recent advances in targeted drug delivery system. Mater Today Commun 2023;35:105877.
21. Rahman MM, Islam MR, Akash S, Harun-Or-Rashid M, Ray TK, Rahaman MS, *et al*. Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance. Biomed Pharmacother 2022;153:113305.
22. Liu J, Li S, Wang J, Li N, Zhou J, Chen H. Application of nano drug delivery system (NDDS) in cancer therapy: A perspective. Recent Pat Anticancer Drug Discov 2023;18:125-32.
23. Jiang L, Li X, Lu YS. Nano-based drug delivery system in breast cancer treatment. Nano 2023;18:2330003.
24. Patil PJ, Sutar SS, Usman M, Patil DN, Dhanavade MJ, Shehzad Q, *et al*. Exploring bioactive peptides as potential therapeutic and biotechnology treasures: A contemporary perspective. Life Sci 2022;301:120637.
25. Botros S, Botros M, Botros N. A comparison of the drug approval process in the United States and Canada. Int J Drug Regul Affairs 2022;10:1-8.
26. Zhang S, Zhang S, Luo S, Tang P, Wan M, Wu D, *et al*. Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: Advance and prospect. J Nanobiotechnol 2022;20:1-27.
27. Kara G, Calin GA, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev 2022;182:114113.
28. Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M. Drug release study of the chitosan-based nanoparticles. Heliyon 2022;15:4.